Faculty

Amalia Londono-Tobon, MD, is a board-certified psychiatrist subspecializing in perinatal and childhood mental health. Amalia obtained her B.A. in Neuroscience from Johns Hopkins University, her M.D. from Stanford University, and her residency training from Yale University. Throughout her academic career, Amalia has conducted basic and clinical research in neurodevelopment and the treatment of mental health disorders.

Katherine Callaghan, MD, is the founder and director of UMassMemorial’s Karen W Green Clinic for Pregnancy and Recovery. This multidisciplinary clinic provides comprehensive prenatal care and addiction treatment to women with a variety of substance use disorders. “The Green Clinic” seeks to optimize and integrate obstetrical & postpartum care, Medication Assisted Treatment, psychiatric services, Peer Support and social work support to women in recovery, seeking recovery or actively using substances. Since joining the Ob/Gyn Department at UMassMemorial in 2014, Katherine has led a committee of nurses, pharmacists, addiction specialists and administrators in drafting, finalizing and implementing in-patient protocols for initiating Medication Assisted Treatment (MAT) in the pregnant patient, including both a methadone protocol and a buprenorphine protocol. These protocols have both improved and streamlined the process, making MAT a readily available option for pregnant women seeking care. 

David A. Fiellin, MD, is a Professor of Medicine, Emergency Medicine and Public Health at Yale.  He Directs the Yale Program in Addiction Medicine and the Clinical and Health Services Research Core at Yale’s Center for Interdisciplinary Research on AIDS.  He is board certified in Internal Medicine and Addiction Medicine. His NIH-funded research is on the interface between substance use and general medical settings including office-based practice, primary care, Emergency Department and HIV specialty settings. He has received awards from the American Association for the Treatment of Opioid Dependence, the American Society of Addiction Medicine, AMERSA, and the Hazelden Betty Ford Foundation. He is Co-Editor of the ASAM textbook, Principles of Addiction Medicine, 4th, 5th and 6th Editions, and on the Editorial Boards of 4 addiction specialty journals. He has served on the Board of Directors of the College on Problems of Drug Dependence and as Co-Chair of the Substance Abuse Interest Group at the Society of General Internal Medicine.  

Leena Mittal, MD, is the Chief of the Division of Women's Mental Health at Brigham and Women's Hospital and an Instructor in Psychiatry at Harvard Medical School, and serves as the Program Director for the Women's Mental Health Fellowship at the Brigham.  Dr. Mittal has numerous publications and speaks nationally on the treatment of mental health and substance use conditions throughout pregnancy and the postpartum period.  Dr. Mittal is board certified in psychiatry, psychosomatic medicine and addiction medicine.   Additionally, Dr. Mittal is the Associate Medical Director for the Massachusetts Child Psychiatry Access Program for Moms (MCPAP for Moms), an innovative statewide consultation service for providers seeing pregnant and postpartum women with mental health and substance use conditions.  

Ariadna Forray, MD, is an Associate Professor of Psychiatry at Yale School of Medicine. She received her B.A. in neuroscience from Bryn Mawr and her M.D. from Harvard. During her psychiatry residency training at Yale she joined the Neuroscience Research Training Program and studied the impact of pregnancy, PTSD and pregnancy-specific anxiety on stress reactivity and arousal using the affect modulation of the acoustic startle reflex. Following residency, she joined the faculty at Yale and was awarded funding through the competitive Clinician Scientist Training Program (K12), and focused her research on the development of novel treatments for perinatal substance use. As a principal investigator and co-investigator on several NIH-funded grants, she has developed and implemented addiction treatment interventions, successfully recruited pregnant women with substance use disorders for participation in clinical research, and collaborated with researchers and clinicians across disciplines. As part of her clinical work, Dr. Forray is an attending on the Behavioral Intervention Team and the Resident Education Director for the Psychological Medicine Service at Yale New Haven Hospital. She is also the Psychiatry Director of the multidisciplinary Adult Sickle Cell Program.

Weitzman Institute Disclosure Statement

It is the policy of the Weitzman Institute to ensure that Continuing Education (CE) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the Weitzman Institute requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

Faculty participating in a Weitzman Institute-sponsored activity must disclose to the planning committee and audience all financial or other relationship(s) with ineligible companies.

Faculty Disclosures

No faculty disclosed a relevant financial relationship for this program.